ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications
Related Experiment Video
Updated: Jul 7, 2025
Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
Flavia Linguanti1,2, Elisabetta Maria Abenavoli3, Raffaella Calabretta4
1Nuclear Medicine Unit, Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
Abstract:
Receptor tyrosine kinases, or RTKs, are one large family of cell surface receptors involved in signal transduction, which represent an integral part of the signaling pathways. They play a crucial role in most important cellular processes, starting with the cell cycle, proliferation and differentiation, as well as cell migration, metabolism and survival. The introduction of ImmunoPET evaluating the expression of RTKs by specific monoclonal antibodies (mAbs) or antibody fragments is regarded as a promising tool for imaging treatment efficacy and developing anticancer therapeutics. Our review focuses mainly on the current clinical research regarding ImmunoPET targeting RTKs, with particular interest in the epidermal growth factor family, or HER family, and vascular endothelial-derived growth factor/receptor.
Insights
ImmunoPET imaging shows promise for evaluating receptor tyrosine kinase (RTK) expression and guiding anticancer therapeutics. This review highlights clinical research on ImmunoPET targeting RTKs, particularly the HER family and VEGF/R.
Area of Science:
- Oncology
- Molecular Imaging
- Biochemistry
Background:
- Receptor tyrosine kinases (RTKs) are key cell surface receptors regulating critical cellular processes like proliferation and survival.
- Dysregulation of RTKs is implicated in various cancers, making them important therapeutic targets.
Purpose of the Study:
- To review current clinical research on ImmunoPET imaging targeting RTKs for cancer therapy.
- To focus on ImmunoPET applications for the epidermal growth factor receptor (HER) family and vascular endothelial growth factor receptor (VEGF/R).
Main Methods:
- Review of existing clinical studies utilizing ImmunoPET for RTK expression analysis.
- Analysis of monoclonal antibodies (mAbs) and antibody fragments as targeting agents in ImmunoPET.
Main Results:
- ImmunoPET is a promising tool for assessing RTK expression and treatment efficacy in cancer.
- Clinical data on ImmunoPET targeting HER family and VEGF/R shows potential for personalized medicine.
Conclusions:
- ImmunoPET offers a non-invasive method to evaluate RTK status in tumors.
- Targeting RTKs with ImmunoPET can aid in developing novel anticancer therapeutics and monitoring treatment response.
More Related Videos
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
11:34Murine Lymphocyte Labeling by 64Cu-Antibody Receptor Targeting for In Vivo Cell Trafficking by PET/CT
Published on: April 29, 2017
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...